NCT07168200

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 720 (estimated)
• Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd · Industry
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).

Conditions

• Advanced Cervical Cancer

Interventions

Type	Name	Description
DRUG	SHR-1316 Injection	SHR-1316 injection.
DRUG	Cisplatin Injection	Cisplatin injection.
DRUG	Carboplatin Injection	Carboplatin injection.
DRUG	Paclitaxel Injection	Paclitaxel injection.
DRUG	SHR-1316 Placebo Injection	SHR-1316 placebo injection.

Timeline

• Start date: 2025-10-17
• Primary completion: 2028-04-01
• Completion: 2028-12-01
• First posted: 2025-09-11
• Last updated: 2026-04-15

Locations

1 site across 1 country: China